BioMed Technology Holdings

BioMed Technology Holdings is a Hong Kong microbiome-health company focused on personalized health management based on microbiome testing and tailored probiotic interventions. Founded in 2018 by professors, physicians, and biomedical scientists affiliated with The Chinese University of Hong Kong, the company provides gut microbiome and related molecular testing, interpretation, and consumer-facing probiotic products under the PGut brand. Its business appears to center on commercial wellness and healthcare services rather than traditional drug development, with offerings spanning gut, oral, and skin microbiome balance. BioMed operates clinical and R&D facilities in Hong Kong and has been supported by investors including Alibaba Entrepreneurs Fund, Gobi Partners, Human Health, and CUHK Innovation. The company positions itself around precision, personalized, and evidence-based microbiome solutions for common urban health problems such as allergies, gut imbalance, and metabolic or lifestyle-related symptoms.